Article Text

Download PDFPDF
Human papillomavirus-independent cervical cancer
  1. Andreina Fernandes1,
  2. David Viveros-Carreño2,
  3. Jorge Hoegl3,
  4. Maira Ávila1 and
  5. Rene Pareja2,4
  1. 1Laboratorio de Genética Molecular, Instituto de Oncología y Hematología, Caracas, Bolivarian Republic of Venezuela
  2. 2Department of Gynecologic Oncology, Instituto Nacional de Cancerologia, Bogota, Colombia
  3. 3Obstetrics and Gynecology. Division of Gynecological Oncology, Hospital General del Este "Dr. Domingo Luciani", Caracas, Bolivarian Republic of Venezuela
  4. 4Clínica ASTORGA, Medellín, Colombia
  1. Correspondence to Dr Rene Pareja, Department of Gynecologic Oncology, Instituto Nacional de Cancerologia, Bogota, Colombia; ajerapener{at}gmail.com

Abstract

Cervical cancer is the fourth most frequent cancer in women worldwide, representing nearly 8% of all female cancer deaths every year. The majority of cases of cervical cancer are caused by human papillomavirus (HPV); however, up to 5% of tumors are not associated with HPV-persistent infection and, moreover, the new WHO Female Genital Tumors classification subdivided cervical squamous and adenocarcinomas into HPV-associated and HPV-independent tumors. Based on this new information, the aim of this review is to provide an overview of HPV-independent cervical cancer, evaluating diagnostic techniques, molecular profiles, and clinical outcomes. The HPV-independent tumors are characterized by a differentiated molecular profile with lower proliferative activity, a p53 immunostaining, a decreased expression of cyclin-dependent kinase inhibitor proteins, such as p16, p14, and p27, and alterations in PTEN, p53, KRAS, CTNNB1, ARID1A, and ARID5B. HPV-independent tumors are associated with both adenocarcinomas and squamous histologic subtypes, with lymph node involvement in the early stages, more distant metastasis, and generally worse oncological outcomes. Thus far, no specific therapeutic strategies have been developed based on HPV status; however, with advancing knowledge of differences in the molecular profiles and possible targetable alterations, novel approaches may offer potential options in the near future. Investigators should report on clinical outcomes, evaluating the overall response rates to specific treatments, and consider new biomarkers to establish more accurate prognostics factors.

  • cervical cancer
  • adenocarcinoma
  • pathology

Statistics from Altmetric.com

Footnotes

  • Twitter @AndreFernandes2, @@dviverosc, @oncohoegl, @@RParejaGineOnco

  • Contributors AF, DV and RP designed the research; DV, JH and MA searched and reviewed the data; AF, DV, JH, MA wrote the paper; RP made the editorial revision. All the authors reviewed the manuscript and approved the final version.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles